Mesa Laboratories, Inc.
MLAB
$98.67
$2.312.40%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.47% | 11.68% | 6.88% | 2.02% | -1.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.47% | 11.68% | 6.88% | 2.02% | -1.32% |
| Cost of Revenue | 8.77% | 3.97% | -1.39% | -3.90% | -4.31% |
| Gross Profit | 13.10% | 16.61% | 12.27% | 5.83% | 0.59% |
| SG&A Expenses | 3.16% | 0.19% | 4.76% | 4.41% | 1.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.13% | 1.89% | 1.50% | 0.46% | -1.51% |
| Operating Income | 376.48% | 7,609.85% | 361.06% | 47.71% | 11.05% |
| Income Before Tax | 102.16% | -45,402.87% | -42,543.50% | -6,727.66% | -70,760.67% |
| Income Tax Expenses | 137.08% | -1,223.10% | -21,395.74% | -1,004.15% | -1,522.59% |
| Earnings from Continuing Operations | 99.22% | -26,412.55% | -34,160.95% | -13,860.80% | -27,438.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 99.22% | -26,412.55% | -34,160.95% | -13,860.80% | -27,438.28% |
| EBIT | 376.48% | 7,609.85% | 361.06% | 47.71% | 11.05% |
| EBITDA | 19.38% | 31.56% | 14.40% | -1.91% | -3.27% |
| EPS Basic | 99.25% | -26,360.65% | -34,455.31% | -13,672.83% | -27,600.29% |
| Normalized Basic EPS | 3,570.63% | 759.91% | 1,427.68% | -38.84% | 124.09% |
| EPS Diluted | 99.22% | -27,716.36% | -31,870.11% | -14,273.25% | -30,125.22% |
| Normalized Diluted EPS | 3,550.40% | 751.94% | 1,405.87% | -38.57% | 122.32% |
| Average Basic Shares Outstanding | 0.61% | 0.61% | 0.70% | 0.88% | 1.23% |
| Average Diluted Shares Outstanding | 0.99% | 0.85% | 0.86% | 0.58% | 0.80% |
| Dividend Per Share | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Payout Ratio | -128.58% | -1.00% | 1.00% | -1.01% | -1.00% |